Top 5 Healthcare Technology Companies To Buy Right Now

The folks at graphics-chip specialist�NVIDIA (NASDAQ: NVDA  ) has certainly been busy of late. In fact, NVIDIA stock is currently trading within 6% of its 52-week-high after the company released solid first-quarter results�last month. The month before, NVIDIA management announced plans to return at least $1 billion to shareholders in the form of dividends and NVIDIA stock repurchases by the end of this year.

In addition, so far in 2013, NVIDIA has already unveiled both its new Tegra 4 and Tegra 4i LTE mobile processors, outlined�roadmaps for more powerful processors going forward, and is close to releasing its own handheld gaming platform, Project Shield.

Anytime, anywhere
What's more, in addition to Shield, the company has released a number of other GRID-enabled products to support its end goals of being able to remotely provide a superior cloud-based graphics experience no matter what the capabilities of your particular device.

Even so, that doesn't mean NVIDIA won't also support other dedicated gaming consoles, such as Microsoft's (NASDAQ: MSFT  ) coming Xbox One, which largely competes with NVIDIA's long-term vision. Remember, a little over two weeks ago, I�noted that NVIDIA�seemed curiously eager to help make games even better for�Microsoft's�new Xbox One console.

Best High Tech Companies To Watch For 2015: Green Dot Corporation (GDOT)

Green Dot Corporation operates as a bank holding company. It offers general purpose reloadable prepaid debit cards, and cash loading and transfer services in the United States. The company�s products include Green Dot MasterCard, Visa-branded prepaid debit cards, and various co-branded reloadable prepaid card programs; Visa-branded gift cards; and MoneyPak and swipe reload proprietary products that enable cash loading and transfer services through its Green Dot Network. Its Green Dot Network enables consumers to use cash to reload its prepaid debit cards or to transfer cash to any of the company�s Green Dot Network acceptance members, including competing prepaid card programs, and other online accounts. The company markets its cards and financial services to banked, underbanked, and unbanked consumers. Green Dot Corporation offers its products and services through retail distributors, including mass merchandisers, drug store and convenience store chains, and supermarket chains; the Internet; and relationships with other businesses. Its prepaid debit cards and prepaid reload services are available to consumers at approximately 60,000 retail locations nationwide and online at greendot.com. The company was formerly known as Next Estate Communications, Inc. and changed its name to Green Dot Corporation in October 2005. Green Dot Corporation was incorporated in 1999 and is headquartered in Pasadena, California.

Advisors' Opinion:

• [By Rich Bieglmeier]

  Green Dot Corporation (GDOT) will host a conference call to discuss third quarter 2013 financial results on Thursday, October 31, 2013 at 4:30pm ET. A press release with third quarter 2013 financial results will be issued after the market closes that same day.

Top 5 Healthcare Technology Companies To Buy Right Now: Vanguard Intermediate Term Bond ETF (BIV)

Vanguard Intermediate-Term Bond ETF (the Fund) seeks to track the performance of a market-weighted bond index with an intermediate-term, dollar-weighted average maturity. The Fund employs a passive management or indexing strategy designed to track the performance of the Barclays Capital U.S. 5-10 Year Government/Credit Bond Index (the Index). The Index includes all medium and larger issues of the United States Government, investment-grade corporate, and investment-grade international dollar-denominated bonds that have maturities between 5 and 10 years and are publicly issued. The Fund invests by sampling the Index, meaning that it holds a range of securities that, in the aggregate, approximate the full Index in terms of key risk factors and other characteristics. All of the Fund�� investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the Index. The Fund�� investment advisor is The Vanguard Group, Inc. Advisors' Opinion:

• [By GURUFOCUS]

  In addition to individual stocks several funds pay a monthly dividend. Below is a sampling of these:
  Monthly Bond Funds- iShares Barclays 1-3 Year Credit Bond (CSJ) | Yield: 1.29%
  - Vanguard Short-Term Bond ETF (BSV) | Yield: 1.25%
  - Vanguard Intermediate-Term Bond ETF (BIV) | Yield: 2.96%
  - Vanguard Long-Term Bond ETF (BLV) | Yield: 4.42%

Top 5 Healthcare Technology Companies To Buy Right Now: Enanta Pharmaceuticals Inc (ENTA)

Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.

In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.

Advisors' Opinion:

• [By James Fink]

  And lastly I'll go into healthcare, which is kind of a growth cyclical type name. It's partially defensive, partially growth. I think the more growth-oriented section of healthcare would be biotech, and right now, a very promising biotech stock is Enanta Pharmaceuticals. That's a NASDAQ stock; ticker symbol (ENTA).

• [By Sean Williams]

  The next big thing in treating hepatitis-C
  The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV  ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA  ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi.

• [By George Budwell]

  Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV  ) , Enanta Pharmaceuticals (NASDAQ: ENTA  ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�

Top 5 Healthcare Technology Companies To Buy Right Now: Harvest Natural Resources Inc (HNR)

Harvest Natural Resources, Inc., incorporated on September 9, 1988, is a petroleum exploration and production company. The Company is engaged in the exploration, development and production of properties in geological basins with proven active hydrocarbon systems. The Company holds interest in the Bolivarian Republic of Venezuela (Venezuela). The Company's Venezuelan interests are owned through Harvest-Vinccler Dutch Holding, B.V. Through HNR Energia, B.V. (HNR Energia), the Company indirectly owns 80% of Harvest Holding and its partner, Oil & Gas Technology Consultants (Netherlands) Cooperatie U.A., indirectly owns the remaining 20% interest of Harvest Holding. Harvest Holding owns, indirectly through wholly owned subsidiaries, a 40% of Petrodelta, S.A. (Petrodelta). The Company indirectly owns a net 32% interest in Petrodelta, and Venezolana de Inversiones y Construcciones Clerico, C.A. (Vinccler) indirectly owns 8%. Corporacion Venezolana del Petroleo S.A. (CVP) owns the remaining 60% of Petrodelta. Petroleos de Venezuela S.A. (PDVS) owns 100% of CVP. Harvest Holding has a direct controlling interest in Harvest Vinccler S.C.A. (Harvest Vinccler).

As of December 31, 2012, the Company's operations were located at Venezuela, Republic of Indonesia, Republic of Gabon, Sultanate of Oman and People's Republic of China. In Venezuela operations are through the Company's Petrodelta. In Republic of Indonesia (Indonesia) the operations are mainly onshore in West Sulawesi in Indonesia through the Budong PSC. The Company owns a 64.51% interest in the Budong PSC. In Republic of Gabon (Gabon) operations are offshore of Gabon through the Dussafu PSC. The Company has a 66.667% interest in the Dussafu PSC. The Company is the operator. In Sultanate of Oman (Oman) the operations are onshore in Oman through the exploration and production sharing agreement (EPSA) Al Ghubar / Qarn Alam license (Block 64 EPSA). The Company has an 80% interest in Block 64 EPSA. The Company is the operator. In People's Republic o! f China (China) the exploration acreage is offshore of China in the South China Sea through the Wab-21 Petroleum Contract (Wab-21). The Company has a 100% interest in the WAB-21 petroleum contract. The Company is the operator.

Petrodelta is engaged the exploration, production, gathering, transportation and storage of hydrocarbons from the Petrodelta Fields. As of December 31, 2012, there were 86 oil and natural gas producing wells and seven water injection wells in the Petrodelta Fields. As of December 31, 2012, there were 15 oil producing wells and four water injection wells in the Tucupita Field. As of December 31, 2012, there were 28 oil producing wells in the Temblador Field. At December 31, 2012, there were 17 oil producing wells and one water injection well in the El Salto field.

Advisors' Opinion:

• [By Tess Stynes]

  Harvest Natural Resources Inc.(HNR) agreed to sell all the company’s interest in Venezuela for $400 million in cash, as the energy company moves forward with its plans to sell itself.� Shares were up 24% at $4.89 premarket.

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Monday’s session are Achillion Pharmaceuticals Inc.(ACHN), Active Network Inc.(ACTV) and Harvest Natural Resources Inc.(HNR)

• [By Paul Ausick]

  Harvest Natural Resources Inc. (NYSE: HNR) is up 17.3% at $4.62. The independent oil & gas company received an upgrade today based on the belief that company can sell some of its foreign assets.